The lat­est Cin­derel­la sto­ry in on­col­o­gy ends with a sud­den rout as up­dat­ed da­ta dis­play spooks in­vestors

NextCure’s turn as the Cin­derel­la of can­cer-fo­cused biotechs was short-lived.

Just a few days af­ter its shares $NXTC zoomed up more than 250% on some very ear­ly stage re­sults in a SITC ab­stract, a more com­plete analy­sis over the week­end spiked the hype and left in­vestors in high dud­geon as the stock price col­lapsed back to­wards earth Mon­day.

The fo­cus at NextCure is cen­tered on NC318, an an­ti­body that is in­tend­ed to shut down the im­muno­sup­pres­sive Siglec-15 — or S-15 — tar­get. Af­ter adding a small group of pa­tients to the read­out, in­ves­ti­ga­tors cir­cled 2 clin­i­cal re­spons­es, a com­plete and par­tial re­sponse, along with 4 sta­ble dis­ease cas­es in non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.